LDL Cholesterol: Normal Range, "Bad Cholesterol" Targets Explained

Your LDL number on a standard lipid panel is almost always calculated, not measured. The lab measures total cholesterol, HDL, and triglycerides directly, then estimates LDL using the Friedewald equation: LDL = Total − HDL − (Triglycerides ÷ 5).

That formula breaks down when triglycerides run high. If your triglycerides are above 400 mg/dL, the calculated LDL is unreliable — insist on a direct LDL measurement or ask whether the lab uses the Martin–Hopkins or Sampson equation, both of which handle high triglycerides better.

What LDL does not tell you: how many particles are actually circulating. Two people can have the same LDL of 130, but one might carry it on a small number of large particles and the other on a much larger number of small dense particles. The second person is at higher risk. That is why ApoB is becoming the preferred marker — it counts particles directly. See Apolipoprotein B below.

The 2026 ACC/AHA guidelines moved away from a single "normal" cutoff and toward risk-based targets. The right LDL for you depends on your overall cardiovascular risk, not on a one-size-fits-all number.

• No risk factors, low 10-year risk: below 100 mg/dL is desirable.
• Diabetes, family history, or moderate risk: below 70 mg/dL is the working target.
• Established cardiovascular disease (had a heart attack, stroke, or stent): below 55 mg/dL, with many cardiologists pushing for under 40.

An LDL of 190 or above on its own is enough to warrant statin therapy regardless of other risk factors — that level strongly suggests familial hypercholesterolemia (FH), which affects roughly 1 in 250 people.

An elevated LDL means more cholesterol-carrying particles are circulating than your liver is clearing. Causes range from genetics to thyroid:

• Genetics. Familial hypercholesterolemia is the headline cause of LDL above 190. It is dramatically underdiagnosed — fewer than 10% of people with FH know they have it.
• Diet. Saturated fat raises LDL more than dietary cholesterol does. Trans fats are the worst per gram.
• Hypothyroidism. Low thyroid function reliably raises LDL by 30–50 mg/dL. Always check TSH before committing to a statin in someone with newly elevated LDL.
• Nephrotic syndrome and chronic kidney disease. Dramatic shifts in lipoproteins.
• Medications. Thiazide diuretics, some beta-blockers, corticosteroids, certain immunosuppressants, and some HIV protease inhibitors.
• Pregnancy. LDL physiologically rises 25–50% in pregnancy and falls back postpartum. Do not interpret pregnancy lipid panels as baseline.

How much can lifestyle move LDL? A strict plant-based diet plus 5–10 g/day of soluble fiber drops LDL by 20–37% in motivated patients. Most people get 5–15%. Statins, by comparison, drop LDL 30–50% (moderate intensity) or 50%+ (high intensity). When LDL is genuinely high, lifestyle alone often cannot get there alone — the math doesn't work.

The clinical answer in 2026: probably not, within ranges achievable by medication. People with naturally very low LDL (in the 30s and 40s, due to PCSK9 loss-of-function variants) have been studied for decades and live longer with less heart disease. Trials of PCSK9 inhibitors that drive LDL into the 20s have not found new safety signals.

What does warrant a workup is spontaneously low LDL — under 50 mg/dL in someone not on lipid-lowering medication. Causes worth checking:

• Hyperthyroidism
• Severe liver disease (the liver makes most circulating LDL)
• Malabsorption (celiac, advanced inflammatory bowel disease)
• Hypobetalipoproteinemia (a rare genetic condition)
• Active malignancy or cachexia

The "lower for longer" principle from the 2026 guidelines specifically endorses driving LDL well below traditional cutoffs over a lifetime in higher-risk patients.

LDL fluctuates roughly 10–15% between tests in the same person. A reading of 138 followed by 122 is not a "drop" — it's noise. What matters:

• The 12–24 month direction. Steady creep upward, even within "normal," is the early signal of accumulating risk.
• The response to a statin. Moderate-intensity statins (atorvastatin 10–20, rosuvastatin 5–10) typically drop LDL 30–50% within 4–6 weeks. High-intensity (atorvastatin 40–80, rosuvastatin 20–40) drops it 50%+. If your numbers haven't moved after 8 weeks, the medication, dose, or your adherence is the question — not "statins don't work for me."
• The total exposure over a lifetime. Cardiovascular risk is approximately the area under your LDL-vs-age curve. An LDL of 130 from age 25 onward is worse than an LDL of 160 starting at 55.

This is the case for tracking lipids over years, not just glancing at the most recent panel. AskAnything stitches every panel you upload into a single trend.

The thresholds that move clinical decisions:

• LDL ≥ 190 mg/dL on a confirmed test — strongly suggests FH; statin therapy regardless of other risk factors.
• LDL ≥ 160 mg/dL with one major risk factor (smoking, family history of premature CAD, hypertension, diabetes) — discuss therapy.
• LDL ≥ 100 mg/dL with established cardiovascular disease — your target should be much lower.
• A jump of more than 30 mg/dL between consecutive panels with no obvious cause — recheck thyroid, review medications, repeat the test.

• HDL Cholesterol — the "good" cholesterol. Higher is generally protective; the total/HDL ratio matters more than either alone.
• Triglycerides — the third leg of the lipid panel. High triglycerides skew the calculated LDL.
• Apolipoprotein B — counts the actual atherogenic particles, not just the cholesterol they carry. The 2026 guidelines now recommend ApoB for people with metabolic syndrome, diabetes, or known cardiovascular disease.
• Lipoprotein(a) — a genetically determined risk factor; everyone should be tested at least once.
• hs-CRP — measures arterial inflammation. Useful alongside lipids in borderline cases.
• Total cholesterol — the headline number; LDL is the substance.